New Opportunity in a Once Mature Market Now on a Growth Track
Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.
TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition? The report forecasts the market size in five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.
The research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Make investment decisions and valuations with confidence using the latest data.
All report data is available in Excel format on request.
Table of Contents
1 Market Guides
1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants
2 Introduction and Market Definition
2.1 An Overview of TB Diagnostics
2.1.1 The New Antigen-Based TBST
2.2 Market Definition
2.2.1 Market Size
2.2.2 Currency
2.2.3 Years
2.2.4 Limitations
2.3 Methodology
2.3.1 Methodology
2.3.2 Sources
2.3.3 Authors
2.4 Healthcare and the IVD Industry
2.4.1 Global Healthcare Spending
2.4.2 Spending on Diagnostics
2.4.3 Important Role of Insurance for Diagnostics
3 Tuberculosis - Current Science
3.1 What is Tuberculosis?
3.1.1 Causes
3.1.2 Pathogenesis
3.1.3 Prevention
3.1.4 Treatment
3.2 Diagnosis
3.2.1 Active TB
3.2.2 Latent TB
3.3 Prevalence
3.3.1 Impact of COVID on TB Prevalence
4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Pharmaceutical/Reagent Supplier
4.1.4 Independent Testing Lab
4.1.5 Public National/regional lab
4.1.6 Hospital lab
4.1.7 Physician Lab
4.1.8 Audit Body
4.1.9 Certification Body
5 Market Trends
5.1 Factors Driving Growth
5.1.1 Increasing Prevalence
5.1.2 Increasing Diagnostic Options
5.1.3 The Aging World
5.1.4 Increased Health Care Spending
5.2 Factors Limiting Growth
5.2.1 The Cost Curve Shrinks the Market
5.2.2 The Diagnostics Dillemma
5.2.3 Adoption Lag and Cost Control
5.3 Diagnostic Technology Development
5.3.1 The Multiplex Opportunity
5.3.2 Shifting Role of Physicians in Diagnosis
5.3.3 Diagnostics Moves Out of the Lab
5.3.4 Rapid Testing Changing Medical Practice
5.3.5 The Next Five Years
6 TB Diagnostics - Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 QIAGEN’s QuantiFERON-TB Gold Plus gains new CE-marking
6.3 PerkinElmer Hopes to Gain Market Share against Qiagen
6.4 PBD Biotech to Develop TB Blood Test
6.5 WHO Expands Assessment for TB MDx Developers
6.6 Cepheid Omni POC System Falls Off Radar
6.7 Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
6.8 NGeneBio Gets CE Mark for NGS-Based TB Assay
6.9 MDx TB Assay From PBD Biotech Shows Promise
6.10 Minute Molecular Dx to Launch Rapid PCR Test
6.11 Qiagen Next-Gen TB Test Gains Chinese Approval
6.12 FIND Invests $21M to Launch POC MDx Platforms
6.13 Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
6.14 Oxford Immunotec to Automate Latent TB Test
6.15 LumiraDx Eyes Test Menu Expansion
6.16 BioMérieux Targeting Hospitals With Desktop Latent TB Test
7 Profiles of Key Companies
7.1 AID GmbH
7.2 Beijing Wantai
7.3 bioMérieux Diagnostics
7.4 Boditech Med, Inc
7.5 Endo International
7.6 Erythra
7.7 Generium
7.8 Glory Biotechnologies Corp
7.9 Lionex Diagnostics & Therapeutics GmbH
7.10 Oxford Immunotec (Perkin Elmer)
7.11 Perkin Elmer
7.12 Qiagen
7.13 R-Biopharm AG
7.14 Sanofi
7.15 SD Biosensor
7.16 Serum Institute of India
7.17 Statens Serum Institut
7.18 Zhifei Longcom
8 Latent TB Global Diagnostic Markets Overview
8.1 Latent TB Diagnostics - Global Market Overview by Country
8.1.1 Table - Global Market by Country
8.1.2 Chart - Global Market by Country
8.2 Global Latent TB Diagnostics Markets Overview by Assay
8.2.1 Table - Global Market by Assay
8.2.2 Chart - Global Market by Assay - Segments Growth
8.2.3 Chart - Global Market by Assay - Share by Year
8.2.4 Chart - Global Market by Assay
8.2.5 Chart - Global Market by Assay - Base Year
8.2.6 Chart - Global Market by Assay - Final Year
8.3 Global Latent TB Diagnostics Markets Overview by Risk Factor
8.3.1 Table - Global Market by Risk Factor
8.3.2 Chart - Global Market by Risk Factor - Segments Growth
8.3.3 Chart - Global Market by Risk Factor - Share by Year
8.3.4 Chart - Global Market by Risk Factor
8.3.5 Chart - Global Market by Risk Factor - Base Year
8.3.6 Chart - Global Market by Risk Factor - Final Year
8.4 Global Latent TB Diagnostics Markets Overview by Lab.
8.4.1 Table - Global Market by Lab
8.4.2 Chart - Global Market by Lab - Segments Growth
8.4.3 Chart - Global Market by Lab - Share by Year
8.4.4 Chart - Global Market by Lab
8.4.5 Chart - Global Market by Lab - Base Year
8.4.6 Chart - Global Market by Lab - Final Year
9 Latent TB Diagnostic Market - by Assay
9.1 Latent TB Diagnostic - TST
9.1.1 Table Latent TB Diagnostic TST - by Country
9.1.2 Chart - Latent TB Diagnostic TST Growth
9.2 Latent TB Diagnostic - IGRA
9.2.1 Table Latent TB Diagnostic IGRA - by Country
9.2.2 Chart - Latent TB Diagnostic IGRA Growth
9.3 Latent TB Diagnostic - TBST
9.3.1 Table Latent TB Diagnostic TBST - by Country
9.3.2 Chart - Latent TB Diagnostic - TBST Growth
9.4 Latent TB Diagnostic -Other
9.4.1 Table Latent TB Diagnostic Other - by Country
9.4.2 Chart - Latent TB Diagnostic - Other Growth
10 Global Latent TB Diagnostics Markets - By Risk Factor
10.1 Latent TB Diagnostic - HIV
10.1.1 Table Latent TB Diagnostic HIV - by Country
10.1.2 Chart - Latent TB Diagnostic HIV Growth
10.2 Latent TB Diagnostic - Pediatric
10.2.1 Table Latent TB Diagnostic Pediatric- by Country
10.2.2 Chart - Latent TB Diagnostic Pediatric
10.3 Latent TB Diagnostic - Diabetes
10.3.1 Table Latent TB Diagnostic Diabetes - by Country
10.3.2 Chart - Latent TB Diagnostic - Diabetes Growth
10.4 Latent TB Diagnostic - Immigration
10.4.1 Table Latent TB Diagnostic Immigration - by Country
10.4.2 Chart - Latent TB Diagnostic - Immigration Growth
10.5 Latent TB Diagnostic - Other Risk Factor
10.5.1 Table Latent TB Diagnostic Other Risk Factor - by Country
10.5.2 Chart - Latent TB Diagnostic - Other Risk Factor Growth
11 Global Latent TB Diagnostics Markets - By Lab/Place
11.1 Latent TB Diagnostic - Hospital Lab
11.1.1 Table Latent TB Diagnostic Hospital Lab - by Country
11.1.2 Chart - Latent TB Diagnostic Hospital Lab Growth
11.2 Latent TB Diagnostic - Outpatient Lab
11.2.1 Table Latent TB Diagnostic Outpatient Lab - by Country
11.2.2 Chart - Latent TB Diagnostic Outpatient Lab Growth
11.3 Latent TB Diagnostic - Point of Care
11.3.1 Table Latent TB Diagnostic Point of Care - by Country
11.3.2 Chart - Latent TB Diagnostic Point of Care
11.4 Latent TB Diagnostic - Other Place
11.4.1 Table Latent TB Diagnostic Other Place - by Country
11.4.2 Chart - Latent TB Diagnostic Other Place
12 Appendices
12.1 United States Medicare System: Clinical Laboratory Fees Schedule
Table of Tables
Table 1 - TST vs IGRA
Table 2 Market Players by Type
Table 3 Five Factors Driving Growth
Table 4 Three Factors Limiting Growth
Table 5 - Global Latent TB Diagnostics Market by Country/Region
Table 6 Global Market by Assay
Table 7 Global Market by Risk Factor
Table 8 Global Market by Lab
Table 9 Latent TB Diagnostic TST by Country
Table 10 Latent TB Diagnostic IGRA by Country
Table 11 Latent TB Diagnostic TBST by Country
Table 12 Latent TB Diagnostic Other by Country
Table 13 Latent TB Diagnostic HIV by Country
Table 14 Latent TB Diagnostic Pediatric by Country
Table 15 Latent TB Diagnostic Diabetes by Country
Table 16 Latent TB Diagnostic Immigration by Country
Table 17 Latent TB Diagnostic Other Risk Factor by Country
Table 18 Latent TB Diagnostic Hospital Lab by Country
Table 19 Latent TB Diagnostic Outpatient Lab by Country
Table 20 Latent TB Diagnostic Point of Care by Country
Table 21 Latent TB Diagnostic Other Place by Country
Table 22 Clinical Lab Fee Schedule
Table of Figures
Figure 1 Global Prevalence of TB - 2019
Figure 2 Global Healthcare Spending Map
Figure 3 The Lab Test Pie - Wholesale and Retail
Figure 4 Percentage of World Population Over 65
Figure 5 Growth in Health Care Spending Developing World
Figure 6 Comparing The New Diagnostics and Traditional Testing
Figure 7 Growth rates of Latent TB Diagnostics
Figure 8 Global Market Share Chart
Figure 9 Latent TB Diagnostics Market Segment Shift Base vs Final year
Figure 10 Latent TB Diagnostics Market by Assay Base Year
Figure 11 Latent TB Diagnostics Market by Assay Final Year
Figure 12 Latent TB Diagnostics Market Segment Shift Base vs Final year
Figure 13 Latent TB Diagnostics Market by Risk Factor Base Year
Figure 14 Latent TB Diagnostics Market by Risk Factor Final Year
Figure 15 Latent TB Diagnostics Market Segment Shift Base vs Final year
Figure 16 Latent TB Diagnostics Market by Lab Base Year
Figure 17 Latent TB Diagnostics Market by Lab Final Year
Figure 18 Latent TB Diagnostic TST Growth
Figure 19 LATENT TB Diagnostics Syndromic POC Panel Growth
Figure 20 Latent TB Diagnostic TBST Growth
Figure 21 Latent TB Diagnostic Other Growth
Figure 22 Latent TB Diagnostic HIV Growth
Figure 23 LATENT TB Diagnostics Pediatric
Figure 24 Latent TB Diagnostic Diabetes Growth
Figure 25 Latent TB Diagnostic Immigration Growth
Figure 26 Latent TB Diagnostic Other Risk Factor Growth
Figure 27 Latent TB Diagnostic Hospital Lab Growth
Figure 28 Latent TB Diagnostic Outpatient Lab Growth
Figure 29 LATENT TB Diagnostics Point of Care
Figure 30 LATENT TB Diagnostics Other Place
Samples
LOADING...
Companies Mentioned
- AID GmbH
- Beijing Wantai
- bioMérieux Diagnostics
- Boditech Med, Inc
- Endo International
- Erythra
- Generium
- Glory Biotechnologies Corp
- Lionex Diagnostics & Therapeutics GmbH
- Oxford Immunotec (Perkin Elmer)
- Perkin Elmer
- Qiagen
- R-Biopharm AG
- Sanofi
- SD Biosensor
- Serum Institute of India
- Statens Serum Institut
- Zhifei Longcom
